Welcome to our dedicated page for Alterity Therapeutics SEC filings (Ticker: PRNAF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alterity Therapeutics Limited (PRNAF) files as a foreign private issuer with the U.S. Securities and Exchange Commission, using Form 20-F for annual reporting and Form 6-K for current reports. This SEC filings page brings together those regulatory documents so investors can review how the company describes its status as a development stage enterprise, its capital markets activity, and selected development milestones.
Recent Form 6-K filings for Alterity Therapeutics Limited include exhibits such as an application for quotation of securities, notifications of cessation of securities, changes in substantial holdings, multiple change of director’s interest notices, and a notice under Section 708A. These filings are also incorporated by reference into the company’s registration statements on Form S-8 and Form F-3, which relate to securities registered for issuance in U.S. markets.
One 6-K filing references an exhibit titled "Alterity Presents Phase 2 Data at US Neurology Meeting," indicating that the company uses its current reports to highlight certain clinical or development updates alongside securities and governance disclosures.
On Stock Titan, this page provides access to Alterity Therapeutics Limited’s SEC filings with AI-powered summaries that explain the key points in plain language. Users can review Form 6-K current reports, understand how they tie into registration statements, and track items such as director interest changes, substantial holding changes, and securities quotation or cessation notices. This helps investors and researchers interpret complex regulatory documents related to PRNAF more efficiently.
ALTERITY THERAPEUTICS LTD director Lawrence Bernard Gozlan has filed an initial Form 3 showing his indirect holdings in the company. The filing reports 4,545,455 ordinary shares held indirectly through Montoya Pty Ltd <Buttercup A/C>.
He also indirectly holds listed options over 1,515,152 ordinary shares with a conversion price of $0.028 per share, expiring on 26 February 2027, and unlisted options over 50,000,000 ordinary shares with a conversion price of $0.010 per share, expiring on 30 December 2027. The Form 3 records these positions as existing holdings rather than new market purchases or sales.
ALTERITY THERAPEUTICS LTD director Julian Michael Babarczy filed an initial Form 3, which is a required disclosure of insider holdings. The filing lists him as a director but shows no reportable transactions, exercises, gifts, or restructurings and no derivative positions in this snapshot.
Alterity Therapeutics director Peter Ashley Marks filed an initial Form 3 reporting his beneficial holdings in the company. He indirectly holds 1,818,182 Ordinary shares through Shanti Capital Pty Ltd <Peter Marks Super Fund A/C>. He also holds listed options over 606,061 Ordinary shares with a conversion price of $0.028 per share expiring on 26 Feb 2027, and unlisted options over 30,000,000 Ordinary shares with a conversion price of $0.010 per share expiring on 30 Dec 2027.
Alterity Therapeutics Chief Financial Officer Abby Sarah Macnish Niven filed an initial ownership report detailing indirect equity interests in the company held through CASAM Investments Pty Ltd.
The filing lists 454,545 ordinary shares and a listed option expiring on 26 Feb 2027 over 151,510 underlying ordinary shares at an exercise price of 0.0280 per share. These entries describe existing indirect holdings rather than new market purchases or sales.
Alterity Therapeutics reported positive regulatory progress for its lead drug ATH434 in Multiple System Atrophy (MSA). After a Type C Meeting, the FDA provided written feedback supporting the company’s clinical pharmacology and non-clinical plans for a planned Phase 3 pivotal trial.
The company now aims to secure FDA agreement on Chemistry, Manufacturing, and Controls (CMC) and the Phase 3 trial design, with an End-of-Phase 2 meeting targeted for mid-year 2026. ATH434 has already shown clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial and additional positive data in an open-label Phase 2 study in advanced MSA, and Alterity is preparing to initiate Phase 3.
Alterity Therapeutics Limited has filed a Form 6-K highlighting its planned participation in the Bell Potter Healthcare Horizons Summit in Sorrento, Australia on 12-13 March 2026. CEO David Stamler, M.D. will join a fireside chat on optimising late-stage clinical trials and hold 1-on-1 investor meetings.
The company is a clinical-stage biotechnology business developing disease-modifying therapies for Multiple System Atrophy (MSA) and related Parkinsonian disorders. Its lead candidate, ATH434, has shown clinically meaningful efficacy in a Phase 2 trial and positive results in an open-label Phase 2 study, and the company is preparing a Phase 3 pivotal trial in MSA.
Alterity Therapeutics filed a Form 6-K to disclose the appointment of Daniel O. Claassen, M.D., M.S. as Chief Medical Advisor beginning in March 2026. Dr. Claassen is a tenured professor of neurology at Vanderbilt University Medical Center and an internationally recognized expert in neurodegenerative diseases, especially movement disorders and multiple system atrophy (MSA).
He previously served as coordinating investigator for Alterity’s Phase 2 study of its lead drug candidate ATH434 in MSA and has led numerous clinical trials across academia and industry. Alterity highlights that ATH434 showed clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial and positive data in an open-label Phase 2 study in advanced MSA, and notes it is preparing a Phase 3 pivotal trial.
Alterity Therapeutics provides a shareholder update highlighting major progress with its lead drug candidate ATH434 for Multiple System Atrophy (MSA) and outlining priorities for 2026. In 2025 the company completed its Phase 2 program in MSA, reporting “resoundingly favourable” results, with ATH434 shown to be safe and well-tolerated and to provide strong signals of efficacy, including slowing disease progression and improving mobility and orthostatic hypotension, with no drug-related serious or severe adverse events compared with placebo. Alterity is now planning a pivotal Phase 3 program in MSA and expects to hold an End-of-Phase 2 meeting with the FDA in mid-2026 to finalize the Phase 3 trial design. The company also reports governance and leadership enhancements, including appointing Julian Babarczy as Chair of the Board and expanding its management team in investor relations and corporate strategy to support potential future commercialization and increased business development.